HealthInvest Partners AB Acquires Shares of 39,573 Janux Therapeutics, Inc. (NASDAQ:JANX)

HealthInvest Partners AB purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 39,573 shares of the company’s stock, valued at approximately $2,078,000. Janux Therapeutics accounts for about 1.0% of HealthInvest Partners AB’s portfolio, making the stock its 26th largest position.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its stake in Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after purchasing an additional 156,675 shares during the last quarter. Lester Murray Antman dba SimplyRich grew its holdings in Janux Therapeutics by 205.3% during the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company’s stock worth $1,301,000 after acquiring an additional 16,351 shares during the last quarter. Algert Global LLC acquired a new position in Janux Therapeutics in the 3rd quarter valued at approximately $1,112,000. Ally Bridge Group NY LLC bought a new position in shares of Janux Therapeutics during the third quarter valued at $4,943,000. Finally, FMR LLC lifted its holdings in shares of Janux Therapeutics by 0.6% during the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Down 3.1 %

Shares of JANX stock opened at $36.01 on Monday. Janux Therapeutics, Inc. has a 52 week low of $13.20 and a 52 week high of $71.71. The firm has a 50 day moving average of $46.27 and a 200-day moving average of $48.10. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -30.78 and a beta of 3.16.

Insiders Place Their Bets

In other news, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the transaction, the chief executive officer now owns 217,054 shares of the company’s stock, valued at $12,196,264.26. This represents a 10.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Andrew Hollman Meyer sold 13,334 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,668 shares of company stock worth $3,582,515. 29.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

JANX has been the subject of a number of recent research reports. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. HC Wainwright increased their price target on Janux Therapeutics from $63.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Stifel Nicolaus lifted their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Finally, William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.